Impact of early blood pressure variability on stroke outcomes after thrombolysis: The SAMURAI rt-PA registry

Stroke

Volumn 44, Issue 3, 2013, Pages 816-818

  Endo, Kaoru ^a   Kario, Kazuomi ^b   Koga, Masatoshi ^a   Nakagawara, Jyoji ^c   Shiokawa, Yoshiaki ^d   Yamagami, Hiroshi ^e   Furui, Eisuke ^f   Kimura, Kazumi ^g   Hasegawa, Yasuhiro ^h   Okada, Yasushi ⁱ   Okuda, Satoshi ^j   Namekawa, Michito ^b   Miyagi, Tetsuya ^a   Osaki, Masato ^a   Minematsu, Kazuo ^a   Toyoda, Kazunori ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c Nakamura Memorial Hospital   (Japan)

^d KYORIN UNIVERSITY   (Japan)

^e KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^f KOHNAN HOSPITAL   (Japan)

^g KAWASAKI MEDICAL SCHOOL   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

Acute stroke; Blood pressure variability; Hypertension; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; ANTIHYPERTENSIVE AGENT;

AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE VARIABILITY; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84876247836     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.681007     Document Type: Article

References (13)

1. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, et al; Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008;39: 3316-3322.
2. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, et al; SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40:2442-2449.
3. Tomii Y, Toyoda K, Nakashima T, Nezu T, Koga M, Yokota C, et al. Effects of hyperacute blood pressure and heart rate on stroke outcomes after intravenous tissue plasminogen activator. J Hypertens. 2011;29:1980-1987.
4. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938-948.
5. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375: 895-905.
6. Tomii Y, Toyoda K, Suzuki R, Naganuma M, Fujinami J, Yokota C, et al. Effects of 24-hour blood pressure and heart rate recorded with ambulatory blood pressure monitoring on recovery from acute ischemic stroke. Stroke. 2011;42:3511-3517.
7. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, et al; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke. 2009;40:3591-3595.
8. Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, et al. II. Cerebral infarction/transient ischemic attack (TIA). J StrokeCerebrovasc Dis. 2011;20(Suppl 4):S31-S73.
9. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711.
10. Schächinger H, Langewitz W, Schmieder RE, Rüddel H. Comparison of parameters for assessing blood pressure and heart rate variability from non-invasive twenty-four-hour blood pressure monitoring. J Hypertens. 1989;7(Suppl 3):81-84.
11. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
12. Yong M, Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial. Stroke. 2008;39: 366-372.
13. Kellert L, Sykora M, Gumbinger C, Herrmann O, Ringleb PA. Blood pressure variability after intravenous thrombolysis in acute stroke does not predict intracerebral hemorrhage but poor outcome. Cerebrovasc Dis. 2012;33:135-140.